Denmark: The Country Behind Ozempic Is Preparing for Life After the GLP-1 Windfall

For much of the past decade, Denmark has been held up as one of Europe’s biotechnology success stories, powered by the global rise of Novo Nordisk’s GLP-1 medicines. Yet the country’s recent experience has also highlighted the risks of relying too heavily on a single company and therapeutic category. As policymakers, investors, and industry leaders look beyond the current obesity and diabetes boom, Denmark is increasingly focused on a broader challenge: how to convert today’s pharmaceutical windfall into a more diversified and resilient life sciences ecosystem for the decades ahead.

The Country That Ozempic Built

In 2023, the Danish pharmaceutical industry’s gross value added increased by more than 50% in a single year. Denmark’s exports grew by 13.4%, more than any other year in recent memory. The country ranked among the fastest-growing economies in Europe, a distinction it shared with no other comparable small, open economy at the time. The cause was not a diversified industrial expansion or a technology boom. It was one company — Novo Nordisk — and one class of drugs: GLP-1 receptor agonists sold under the brand names Ozempic and Wegovy.

By the metrics that typically measure national economic health, Denmark was a success story. Novo Nordisk’s market capitalization exceeded Denmark’s entire GDP, an extraordinary concentration of corporate value in a single entity for a high-income European nation. Eight of the twenty-five companies in the Copenhagen stock market index were life sciences companies. Pharmaceutical exports drove growth that analysts described as a once-in-a-generation windfall.

Then, in 2025, Novo Nordisk cut its guidance. Multiple times. Competition in the GLP-1 market intensified as Eli Lilly’s tirzepatide gained share and the first generic alternatives moved toward the market. Novo announced layoffs of approximately 9,000 employees (about 11% of its global workforce), more than half of them in Denmark. Denmark’s 2025 GDP growth forecast was revised downward by 50% — from 3% to 1.4% — in a single announcement.

The pharmaceutical industry had not collapsed. It had merely slowed. And yet the effect on a national forecast was immediate and headline-sized. The dependency that Denmark’s unusual biotech success had created was suddenly, clearly visible.

The Architecture Beneath the Headlines

The Novo Nordisk story tends to crowd out a more textured reality. Denmark’s biotech ecosystem is not simply one company and its supply chain. It is one of the most dense, institutionally supported, and historically deep pharmaceutical clusters in Europe — one that pre-dates the GLP-1 boom by decades and has continued developing alongside it.

Greater Copenhagen anchors Novo Nordisk, Lundbeck, Genmab, Zealand Pharma, Bavarian Nordic, and ALK-Abelló — a concentration of therapeutically diverse, commercially significant companies that few European cities of comparable size can match. Lundbeck has shaped global CNS and psychiatric drug development for more than a century. Genmab, founded in 1999, has become a global leader in antibody therapeutics, with eight commercially approved antibody medicines and blockbuster partnerships with AbbVie, GSK, and Johnson & Johnson, generating royalties at a scale that has allowed it to transition progressively toward a wholly-owned commercial model. Zealand Pharma has built a peptide chemistry platform that has made it one of the most consistently relevant mid-sized biotechs in the GLP-1 and rare disease space. Bavarian Nordic manufactures the MVA-BN smallpox and monkeypox vaccine platform — a product whose global relevance became acutely apparent during the 2022 monkeypox outbreak, when it was the only approved vaccine available at scale.

The biologics contract development and manufacturing layer adds further depth. FUJIFILM Diosynth Biotechnologies Denmark, operating in Hillerød, and AGC Biologics Denmark, in Søborg, both operate at commercial-scale biologics manufacturing, providing Denmark with a CDMO infrastructure that attracts global pharmaceutical clients beyond domestic needs. AGC Biologics committed $239 million to major upgrades in the region, a signal of the confidence that global manufacturing groups place in the cluster’s long-term trajectory.

None of this is Novo Nordisk. All of it is real.

Medicon Valley: The Cross-Border Model

One of Denmark’s most structurally distinctive assets is also one of its least visible outside the industry: Medicon Valley, the cross-border life sciences cluster that spans Copenhagen and the surrounding Danish region on one side of the Øresund strait, and Malmö and Lund in southern Sweden on the other. Connected physically by the Øresund Bridge since 2000 and institutionally by the Medicon Valley Alliance since 1997, the cluster encompasses a population of 3.9 million people, 12 universities, eight university hospitals, and more than 330 member organizations ranging from large pharma to CDMOs to early-stage incubators.

The cluster is the only cross-border life sciences organization that Denmark and Sweden share, and its structural distinctiveness is worth noting: it treats national boundaries as infrastructure problems to be solved rather than market definitions to be respected. Research collaborations run across the Øresund. Talent circulates between Copenhagen’s University of Copenhagen and Lund University’s Faculty of Medicine. Clinical trial networks span both regulatory jurisdictions. The Swedish Karolinska-adjacent cluster and the Danish Greater Copenhagen cluster, which would be formidable in isolation, become genuinely exceptional in combination.

The cluster hosts not only its homegrown anchors but international branches of AbbVie, Pfizer, Amgen, Bayer, Astellas, and Daiichi Sankyo, alongside CDMOs including Polypeptide, Sever Pharma, AGC Biologics, and FUJIFILM Diosynth. The European Spallation Source (ESS) in Lund — set to become the world’s most powerful neutron source — provides the region with research infrastructure relevant to structural biology and drug development that no other European life sciences cluster currently possesses at comparable scale.

The BII Bet: Philanthropic Capital as Ecosystem Engine

Denmark’s most significant strategic move in the current period is not being made by its government. It is being made by a foundation.

In January 2026, the Novo Nordisk Foundation allocated up to DKK 5.5 billion (~€736 million / ~$850 million) to the BioInnovation Institute (BII) in a funding framework running from 2026 through 2035. The BII, a Copenhagen-based nonprofit established in 2018, exists specifically to address the problem that Denmark — and Europe more broadly — has most consistently failed to solve: turning world-class scientific research into commercially viable companies at scale.

Since its founding, BII has helped create and develop more than 130 companies, which have collectively attracted more than DKK 7 billion (~$1.09 billion) in external funding. Venture capital investment into Danish biotech has increased more than fourfold since BII’s establishment. The new ten-year commitment is designed to expand BII’s mandate beyond classic life science startups into artificial intelligence, quantum technologies, and deep tech — fields converging with biotechnology in drug discovery, diagnostics, and biomanufacturing — and to extend its geographic reach across European innovation districts beyond Denmark.

The Novo Nordisk Foundation itself holds an endowment of approximately US$220 billion, making it one of the largest philanthropic foundations in the world. Its wealth derives from its controlling shareholding in both Novo Nordisk and Novonesis (formerly Novozymes). The BII commitment is, at one level, the GLP-1 boom recycled into ecosystem infrastructure — the returns from the drug that concentrated Denmark’s economic risk being deployed to build the diversified innovation base that reduces it.

The logic is transparent and, for a country in Denmark’s position, arguably the most constructive use of that windfall available.

The Commercialization Problem Denmark Is Trying to Solve

It has been reported that the BII investment is explicitly designed to address what its leadership describes as Europe’s most persistent structural failure: the region produces world-class research but has fewer entrepreneurs who have built companies from early science to commercial scale, less risk capital at the critical growth stages, and less of the cultural infrastructure that sustains serial company-building.

This is not a problem unique to Denmark, but Denmark has an unusual ability to fund its own solution. The question is whether philanthropic capital — even at €736 million over ten years — is sufficient to change the structural incentives that make European biotech exits and licensing more attractive than independent commercial growth.

The evidence from BII’s first seven years is cautiously positive. The institute’s Venture Lab, Bio Studio, and Quantum Lab programs collectively offer support up to €3 million per project, providing a bridge between academic proof-of-concept and the commercial financing round that follows. That bridge is where European biotech historically loses companies to U.S. acquirers or to licensing arrangements that extract value from the originating ecosystem.

Among the latest Danish companies to emerge from this pipeline are Troya Therapeutics, focused on protein engineering, and Sulis Therapeutics, developing STING inhibitors. Both represent the BII’s expanding therapeutic range — away from pure metabolic disease, where Denmark’s history is deepest, and toward immunology and precision oncology, where the next generation of global biotech value is being created.

The Concentration Risk Conversation Nobody Wants to Have

Denmark’s Economy Minister Stephanie Lose, when asked about Novo Nordisk’s 2025 slowdown and its effect on the national GDP forecast, was measured in her assessment: lower growth rates at Novo Nordisk were “not a systemic concern,” she said, because much of the company’s contribution to growth comes from activities abroad, including manufacturing in the United States, and the broader Danish economy had strengths beyond pharmaceuticals. The 2025 GDP forecast was subsequently revised upward to 2.6% by December — one of the fastest growth rates in Europe — as the pharmaceutical industry outperformed revised expectations.

The technical accuracy of the minister’s framing does not resolve the underlying structural question. A country whose pharmaceutical industry’s gross value added can increase by more than 50% in a single year, and whose GDP growth forecast can be cut in half by a single company’s guidance revision, is operating with a level of sectoral concentration that no economic diversification narrative fully neutralizes. Ozempic’s core patent expires in 2026 in China and in 2031–2032 in Europe and the United States, creating a patent cliff timeline that the Danish policy conversation is only beginning to engage with directly.

What the BII investment and the broader ecosystem build-out represent is the most credible long-term answer available: not denial of the concentration risk, but active investment in the companies, capabilities, and institutions that will matter after the current GLP-1 cycle has run its course. The Novo Nordisk Foundation is, in this reading, doing with its GLP-1 windfall precisely what sovereign wealth funds are supposed to do with resource revenues — investing it in the productive infrastructure of a post-resource future.

Whether Denmark’s ecosystem can produce the next Genmab, the next Zealand Pharma, or the next Novo Nordisk on a timeline that matters is the question the BII’s ten-year commitment is designed to answer. As BII CEO Jens Nielsen has said: “We have proven that our innovation platform is successful, but we cannot push the boundaries of innovation alone.” The €736 million is the foundation’s answer to what “not alone” requires.

What Denmark’s Model Offers the Broader European Conversation

Beyond its specific national dynamics, Denmark’s current strategic moment offers a template that other European life sciences ecosystems are watching carefully.

The BII model — a well-capitalized, independent nonprofit that bridges academic research and commercial capital, operating with a long-horizon mandate rather than annual funding cycles — addresses the fragmentation that afflicts most European innovation ecosystems. European universities produce extraordinary science. European venture capital, though growing, remains structurally shallower than U.S. pools at the growth stage. The BII’s explicit purpose is to sit in the gap between those two realities and reduce its width.

The Medicon Valley model — a deliberately cross-border cluster that treats a national boundary as an administrative inconvenience rather than a market definition — offers a different kind of template: the demonstration that life sciences ecosystems can be built at a scale that exceeds what any single European country can sustain alone, without requiring full political integration to function.

And the Novo Nordisk Foundation’s use of enterprise foundation returns to fund broad-based innovation infrastructure — rather than simply maximizing distributions or reinvesting exclusively in the originating company — is a model of philanthropic capital allocation that the EU’s own discussions about closing the research-to-commercialization gap frequently invoke but rarely produce at comparable scale.

Denmark’s challenge is a version of the challenge facing every economy that has built concentrated excellence in a single sector: to use that excellence as a foundation for something broader before the cycle turns. The country has the capital, the institutions, and the ecosystems to attempt it. The ten years from 2026 to 2035, the horizon of the BII commitment, will be the period in which the attempt either proves itself or doesn’t.

Author

Bernice Lottering

Related Post

Perspectives

The GLP-1 Gold Rush: Lilly, Novo and New Rivals Chase a $260 Billion Market

2026-03-04

Ranking & Reports

[Illustrations] Global Blockbuster Drug Landscape Shifts in 2026: Keytruda Defends No. 1, “Diabesity” Rivals Surge, IRA Price Caps Take Effect

2026-01-22

Prime

JPM 2026 Recap: Capital Markets Reopen, AI Moves to the Last Mile, Metabolic Stakes Climb

2026-01-15